REG - OptiBiotix Health - Launch of GoFigure range with Apollo Hospitals

OptiBiotix HealthAnnouncement

20/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220920:nRST8392Za&default-theme=true

RNS Number : 8392Z  OptiBiotix Health PLC  20 September 2022

    OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

Launch of GoFigure range with Apollo Hospitals & Pharmacies in India

 

OptiBiotix Ltd, a wholly owned subsidiary of OptiBiotix Health plc (AIM: OPTI)
and a life sciences business developing patented science and human study-based
compounds that modulate the microbiome to address a range of health related
issues such as metabolic syndrome and diabetes, systemic low-grade
inflammation, obesity, cardiovascular disease, high cholesterol and healthy
aging announces, further to the exclusive sales agreement announced 9 December
2021, that its GoFigure range was officially launched by Apollo Hospitals
& Pharmacies on 18 September 2022.

 

Apollo Pharmacies (https://www.apollopharmacy.in/
(https://www.apollopharmacy.in/) ), owned by Apollo Hospitals through Apollo
Healthco, is the largest and most trusted branded pharmacy networks, with
5,000 pharmacy outlets throughout India.

 

GoFigure is OptiBiotix's direct-to-consumer (D2C) (https://gofigurediet.com/
(https://gofigurediet.com/) ) range of weight management products which
combines various meal replacement, healthy snacking options and powdered
beverages containing its multi award winning weight management ingredient
SlimBiome®. The GoFigure portfolio is available for retailers and pharmacies
worldwide.

 

SlimBiome® is OptiBiotix's proprietary weight management aid. It supports
people on a calorie restricted diet to lose weight faster. Human studies show
that it reduces hunger, makes you feel full for longer, reduces food cravings
and uniquely changes the microbiome over time in the direction of a lean
person's microbiome. SlimBiome® carries a wealth of health claims and is
available to formulators worldwide.

 

Apollo's GoFigure product launch consists of meal replacement shakes and
powdered beverage shots and will be expanded over time with extra flavours and
new product forms such as bars. OptiBiotix is responsible for product
development and manufacturing locally in India and has tailored the range
jointly with the Apollo team to suit the unique needs of Indian consumers.

 

The launch has taken place both in store as well as on the newly created
Apollo 24|7 online customer platform. Initially the product will be available
in 120 top stores in major cities across India and then expanded from there.
 

 

René Kamminga, CEO of OptiBiotix Limited, commented: "We are very pleased
that our GoFigure products are now available to the consumer in India through
Apollo Pharmacies, a leading pharmacy chain in India. Our GoFigure range of
weight management products have been specifically formulated to support
consumers on a weight loss journey by reducing hunger and food cravings as
well as modifying the gut microbiome in the direction of a lean person. 18
September marks both the 40(th) anniversary of the group and the 5000(th)
pharmacy opening for Apollo so it is significant to launch on this memorable
day. This launch is another important step in building sales and brand
presence for OptiBiotix's solutions with major partners around the world."

 

This announcement contains inside information for the purposes of UK Market
Abuse Regulation and the Directors of the Company are responsible for the
release of this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                                     www.optibiotix.com (http://www.optibiotix.com/)
 Stephen O'Hara, Chief Executive  Contact via Walbrook below
 OptiBiotix Health Ltd

 Rene Kamminga

 Cairn Financial Advisers LLP (NOMAD)                      Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Cenkos Securities plc (Broker)                            Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                           Mob: 07876 741 001
 Anna Dunphy

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFFLAEIDLIF